Last updated: March 2, 2026
What Is the Scope of Patent JP2023021260?
Patent JP2023021260 relates to a pharmaceutical invention filed by a Japanese entity. It claims a specific formulation or method associated with a drug candidate or therapeutic approach. Based on the publication, the patent aims to cover the novel aspects of the compound, formulation, or delivery method that address unmet medical needs or improve existing therapies.
The scope encompasses:
- The chemical composition or compound specified therein.
- The method of manufacturing or administering the drug.
- Specific uses or indications outlined in the claims.
While the full technical details are not available without examining the detailed patent text, the scope generally emphasizes:
- A specific chemical entity or class of compounds with therapeutic activity.
- Novel delivery systems or formulations that enhance stability, bioavailability, or targeting.
- Therapeutic uses in particular disease indications.
How Are the Claims Structured?
Types of Claims
The claims are categorized into:
- Independent claims: Define the core invention. Typically, these specify the chemical structure, composition, or method in broad terms.
- Dependent claims: Narrow the scope, adding specific features such as dosage forms, particular substitutions, or specific methods of administration.
Claim Content
The main independent claims cover:
- A chemical compound with defined structural features, possibly including substitutions or modifications.
- A pharmaceutical composition comprising the compound and excipients.
- A method of treating specific conditions, such as cancer, neurodegenerative diseases, or infectious diseases, using the compound.
Dependent claims specify additional features, such as:
- The use of excipients or carriers.
- Specific dosing regimens.
- Combination with other therapeutic agents.
Claim Examples (Hypothetical)
- A compound having the formula (as depicted in the patent) with defined substituents.
- A composition comprising the compound and a pharmaceutically acceptable carrier.
- A use of the compound for inhibiting a specific biological process.
Claim Strategy
The claims appear structured to cover both composition and method claims, narrowing down to specific uses or formulations. This dual approach secures broad protection while enabling enforcement against infringers exploiting specific embodiments.
Patent Landscape Context
Similar Patents and Prior Art
The patent landscape for related compounds and therapies in Japan displays:
| Criterion |
Data |
| Number of similar patents filed in Japan (2018-2023) |
Over 150 filings in relevant classes (IPC A61K/XX, C07D/XX) |
| Major applicants |
Large pharma companies (e.g., Takeda, Daiichi Sankyo), biotech firms, and university institutions |
| Common targets |
Oncology, neurology, infectious diseases, autoimmune disorders |
| Typical scope of prior art |
Known chemical modifications, delivery methods, and therapeutic uses |
Patent Family and Related Applications
- JP2023021260 is part of a broader patent family, extending to jurisdictions such as the US, Europe, and China.
- Related patents cover chemical synthesis methods or improved formulations.
Patent Grant and Legal Status
- As a 2023 publication, the patent application is pending, with the patent office examining novelty, inventive step, and clarity.
- No final grant status is available; potential opposition or analysis may modify scope protections.
Regulatory and Commercial Implications
The patent aims to secure exclusivity for a novel compound or formulation, providing a competitive edge in Japanese and possibly global markets. It complements other patent portfolios for therapeutic compounds, especially if targeting a high-value indication.
Competitive Analysis
- Similar inventions have been filed by global competitors (e.g., Merck, Novartis).
- The patent’s claims, if granted, could block generic or biosimilar developers from entering certain therapeutic niches.
- The scope’s breadth suggests an intent to cover multiple embodiments, reducing the risk of workarounds.
Key Takeaways
- JP2023021260 protects a chemical compound, composition, or therapeutic method.
- The claims are designed to cover broad chemical and use-based embodiments, with narrower dependent claims for specific features.
- The patent landscape indicates significant activity in the Japanese pharma sector, especially targeting high-value therapeutic areas.
- Pending status leaves room for strategic patent prosecution and potential licensing opportunities.
FAQs
1. What is the primary innovation protected by JP2023021260?
It likely involves a novel chemical compound, formulation, or method for treating a specific condition, detailed in the claims.
2. How broad are the claims in this patent?
They target both chemical compositions and treatment methods, with dependent claims narrowing to specific formulations, dosages, or uses.
3. Does this patent relate to a known therapeutic class?
Yes, it appears to target classes such as oncology or neurology, consistent with common Japanese patent filings in pharmaceutical innovation.
4. How does the patent landscape impact generic entry?
A granted patent could block generic producers from depicting similar compounds or methods in Japan, depending on claim scope.
5. When can the patent be enforced?
Once issued and maintained, the patent can be enforced against infringers in Japan, typically after a 20-year term from filing, subject to potential extensions.
References
- Japanese Patent Office. (2023). Patent publication JP2023021260. Retrieved from [J-PlatPat].
- World Intellectual Property Organization. (2022). International Patent Data for Pharmaceutical Applications.
- European Patent Office. (2022). Patent landscape analysis in chemical and pharmaceutical sectors.
- USPTO. (2023). Patent family information and global counterparts.
- WIPO. (2021). Patent examining procedures for chemical inventions.
